ONCO vs. ATXI, CNSP, SXTP, CMND, ARDS, VRPX, NTBL, SNOA, CWBR, and SLRX
Should you be buying Onconetix stock or one of its competitors? The main competitors of Onconetix include Avenue Therapeutics (ATXI), CNS Pharmaceuticals (CNSP), 60 Degrees Pharmaceuticals (SXTP), Clearmind Medicine (CMND), Aridis Pharmaceuticals (ARDS), Virpax Pharmaceuticals (VRPX), Notable Labs (NTBL), Sonoma Pharmaceuticals (SNOA), CohBar (CWBR), and Salarius Pharmaceuticals (SLRX). These companies are all part of the "pharmaceutical preparations" industry.
Onconetix (NASDAQ:ONCO) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk.
Avenue Therapeutics received 147 more outperform votes than Onconetix when rated by MarketBeat users.
Onconetix has a beta of 3.34, indicating that its share price is 234% more volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500.
23.9% of Onconetix shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 19.5% of Onconetix shares are owned by company insiders. Comparatively, 1.8% of Avenue Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Avenue Therapeutics' return on equity of 0.00% beat Onconetix's return on equity.
Avenue Therapeutics has lower revenue, but higher earnings than Onconetix. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Onconetix, indicating that it is currently the more affordable of the two stocks.
In the previous week, Avenue Therapeutics had 3 more articles in the media than Onconetix. MarketBeat recorded 6 mentions for Avenue Therapeutics and 3 mentions for Onconetix. Onconetix's average media sentiment score of 0.96 beat Avenue Therapeutics' score of 0.51 indicating that Onconetix is being referred to more favorably in the media.
Summary
Onconetix beats Avenue Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Onconetix News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONCO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Onconetix Competitors List
Related Companies and Tools
